Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX EBIT

EBIT at other companies

Avanos Medical logo
Avanos MedicalAVNS
$8.9M-13.6%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$30.9M+42.5%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Calculated from Pacira BioSciences, Inc.’s reported figures.

$6.9Moperating income+$5.0Mincome before tax+$3.7Minterest expense=$6.9M

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s EBIT?
Pacira BioSciences, Inc. (PCRX) reported EBIT of $6.9M in Q1 2026.
How has Pacira BioSciences, Inc.'s EBIT changed year-over-year?
Pacira BioSciences, Inc.'s EBIT increased by 246.8% year-over-year, from $1.99M to $6.9M.
What is the long-term trend for Pacira BioSciences, Inc.'s EBIT?
Over 2 years (2021 to 2025), Pacira BioSciences, Inc.'s EBIT has grown at a -53.8% compound annual growth rate (CAGR), from $89.92M to $19.19M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.